USPTO serial 79349962
INOVIQ
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 17, 2024
- Examiner
- BRUNDAGE, DAVID WILLIAM
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with INOVIQ?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Charles G. Zug
Charles G. Zug Nelson Mullins Riley & Scarborough LLP301 South College StreetSuite 2300, IP DepartmentCharlotte, NC 28202Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, biotechnology and medical preparations and substances for the prevention, diagnosis or treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases; pharmaceutical, biotechnology and medical preparations and substances for the treatment, reconstruction and repair of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases using antibodies or exosomes; diagnostic preparations and reagents for medical purposes; diagnostic preparations for medical laboratory use and reagents for medical diagnostic use, namely, extracellular vesicles, RNA, protein arrays or monoclonal antibodies; monoclonal antibodies for medical purposes; monoclonal antibody fragments for medical purposes; monoclonal antibody conjugates for medical purposes; preparations for the treatment, reconstruction and repair of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases using antibodies; immunological antibodies for medical use; monoclonal antibodies for diagnostic medical use; monoclonal antibodies for medical use; monoclonal antibodies for therapeutic purposes; products containing antibodies for use in medicine, namely, extracellular vesicles, RNA, protein arrays or monoclonal antibodies; proteins for medical use in binding antibodies; proteins for medical use in detecting antibodies; reagents for use in the development of monoclonal antibodies for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancer viral or bacterial infection; vaccines for human use; vaccine adjuvants; diagnostic preparations, reagents, pharmaceutical and biochemical anti-cancer substances, products for the prevention, diagnosis or treatment of cancer, neurodegenerative, inflammatory, and metabolic diseases, and testing materials, namely, diagnostic test strips, immunoassays, PCR or genetic tests for in-vitro diagnostic use for medical purposes; diagnostic preparations and reagents for medical purposes, namely, diagnostic biomarker reagents; reagents for use in diagnostic tests for medical purposes; reagents for medical diagnosis; proteins for use in recombinant DNA technology for medical diagnosis purposes; proteins, namely protein arrays for use in recombinant DNA technology for medical diagnosis purposes; biological reagents for use in molecular biology for medical purposes | ACTIVE | — |
| 010 | Biotechnology medical apparatus for the prevention, diagnosis or treatment of cancer, neurodegenerative, inflammatory, and metabolic diseases; biotechnology medical apparatus, namely, medical apparatus for the capture of extracellular vesicles; medical diagnostic apparatus and instruments for testing biofluids, plasma, serum, saliva, urine and cell cultures for sale in kit form | ACTIVE | — |
| 042 | Scientific research, clinical research, development, advisory and consultancy services in relation to antibody production; vaccine screening, in the nature of research and development of vaccines; advisory services relating to diagnostic products for scientific research; advisory services relating to diagnostic products for scientific research, namely development of diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; computer-aided diagnostic testing services for others for scientific research purposes; scientific research for medical purposes; scientific research for medical purposes, namely, research services relating to diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; research services in the field of diagnostic preparations; preparation of reports relating to medical, scientific and technical research; provision of information relating to medical, scientific and technical research; research and development of products; research and development of products in the field of antibody generation; research and development of products, namely, new therapeutic products in the field of gene therapeutics and cell therapeutics; research and development of products, namely, extracellular vesicle-based diagnostic products, extracellular vesicle-based therapeutic products; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; laboratory research services relating to research in the field of extracellular vesicle-based diagnostics and extracellular vesicle-based therapeutics; scientific laboratory research and analysis services; scientific laboratory research and analysis services for research and analysis of new products in the field of cell therapeutics; scientific laboratory research and analysis services for research and analysis of new products, namely, extracellular vesicle-based diagnostic products, extracellular vesicle-based therapeutic products; analysis of tissues for medical research; research and development services in the field of antibody generation; molecular target discovery and development services; recombinant human protein production cell line, namely, culturing of cells for others for scientific research purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by INOVIQ Limited
- Other trademarks owned by INOVIQ Limited
- Other trademarks owned by INOVIQ Limited
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named INOVIQ
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 6, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 19, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 19, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 17, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 17, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 17, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 15, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 15, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 25, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 11, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 11, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 11, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 11, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 11, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 7, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 7, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 7, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 11, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 26, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 21, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 21, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Feb 7, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 7, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 22, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 21, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 10, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 24, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 20, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 16, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |